Quote For Genzyme Corporation GENZ.O
sector: Healthcare ·
industry: Biotechnology ·
As of
25 Nov 2009
51.52USD
$51.52
25 Nov 2009
+2.26%
$51.52
--
3,283,069
$0.00
$0.00
$73.75
$47.09
0.31
6,350,807
News
Press Releases
Key Developments
Officers
| Name |
Current Position |
Compensation |
| Termeer, Henri |
Chairman of the Board, President, Chief Executive Officer |
13,773,800 |
| Wyzga, Michael |
Chief Financial Officer, Executive Vice President - Finance |
3,019,200 |
| Wirth, Peter |
Executive Vice President - Legal and Corporate Development, Secretary |
3,246,360 |
Key Ratios and Statistics
| Share Related Items |
| Market Cap (Mil.) |
$13,926.29 |
| Shares Outstanding (Mil.) |
270.31 |
| Float (Mil.) |
262.20 |
| |
| Dividend Information |
| Yield % |
-99,999.99 |
| Annual Dividend ($ USD) |
0.00 |
| Payout Ratio(TTM) % |
0.00 |
| |
| Financial Strength |
| Quick Ratio |
2.26 |
| Current Ratio |
2.55 |
| LT Debt/Equity |
1.55 |
| Total Debt/Equity |
1.66 |
| |
| Valuation Ratios |
| Price/Earnings(TTM) |
29.38 |
| Price/Sales(TTM) |
3.02 |
| Price/Book(TTM) |
1.80 |
| Price/Cash Flow(TTM) |
15.24 |
| |
|
| Per Share Data |
| Earnings(TTM) |
$1.80 |
| Sales(TTM) |
$16.59 |
| Book Value(MRQ) |
$28.70 |
| Cash Flow(TTM) |
$3.29 |
| Cash(MRQ) |
$3.20 |
|
| Management Effectiveness |
| Return on Equity(TTM) |
6.54 |
| Return on Assets(TTM) |
5.01 |
| Return on Investment(TTM) |
5.78 |
| |
|
| Margins |
| Gross Margin(TTM) % |
71.65 |
| Operating Margin(TTM) % |
13.98 |
| Profit Margin(TTM) % |
10.54 |
|
| |
|
UK
US
- Europe
- Asia
- UK Most Actives